Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Ergomed LSE:ERGO London Ordinary Share GB00BN7ZCY67 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 192.50p 190.00p 195.00p 192.50p 192.50p 192.50p 7,500 07:30:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 39.2 0.3 1.3 148.1 76.47

Ergomed (ERGO) Latest News

More Ergomed News
Ergomed Takeover Rumours

Ergomed (ERGO) Share Charts

1 Year Ergomed Chart

1 Year Ergomed Chart

1 Month Ergomed Chart

1 Month Ergomed Chart

Intraday Ergomed Chart

Intraday Ergomed Chart

Ergomed (ERGO) Discussions and Chat

Ergomed Forums and Chat

Date Time Title Posts
24/7/201710:06Ergomed PLC177
06/7/201621:28Stephen Stamp, CFO of Ergomed (ERGO)-

Add a New Thread

Ergomed (ERGO) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-07-28 12:52:03192.501,2502,406.25O
View all Ergomed trades in real-time

Ergomed (ERGO) Top Chat Posts

DateSubject
29/7/2017
09:20
Ergomed Daily Update: Ergomed is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ERGO. The last closing price for Ergomed was 192.50p.
Ergomed has a 4 week average price of 192.50p and a 12 week average price of 190.50p.
The 1 year high share price is 216.50p while the 1 year low share price is currently 118p.
There are currently 39,725,901 shares in issue and the average daily traded volume is 11,878 shares. The market capitalisation of Ergomed is £76,472,359.43.
08/6/2017
22:25
timbo003: The Leeds seminar is a bit too far for me to travel on Tuesday 13th, so I'll hang on and go along to the AGM instead on Friday 16th June which will be held at 265 the Strand in Central London, I'm not too keen on the 09:30 start time though! I see there has been quite a bit of news from Cel-Sci over the last few days: https://uk.advfn.com/stock-market/AMEX/CVM/share-news/CEL-SCI-Extends-the-Expiration-Date-of-Series-DD-W/74947050 They submitted yet another response to FDA on June 5th, so we now have another 30 day wait for further FDA feedback. They are also extending the term of some out of the money warrants from June 8, 2017 to July 10, 2017 which are exercisable at $0.18. The current share price is quoted at $0.0997, so someone in the company is hopeful that FDA will relent and let the Head and Neck cancer study recommence.
24/5/2017
13:58
timbo003: I wonder how long they can carry on without another fund raise? The share price movements today should give us a clue:
22/5/2017
16:47
timbo003: The share price action isn't giving much away, up around 4% on the day
26/1/2017
19:31
bermudashorts: Timbo, As always thanks very much for taking the time and trouble to share another comprehensive report. Lucky escape indeed,which sort of brings me to my question. Do you have any concerns regarding the drive on the co-development front? 10 ongoing projects at any one point in time is quite a commitment and not without risk. 2 or 3 failures in a row could be quite damaging. I should add, not necessarily in financial terms but in regards to sentiment. I guess time will tell and it only takes one or two successes to validate the strategy. Meanwhile the share price continues to go from strength to strength. As I posted over on LSE, I wish the 3 month chart for the rest of my portfolio looked like this.
22/7/2016
11:50
timbo003: I'm not invested here but they are on my watch list and I attended the ShareSoc presentation yesterday so thought I would do a few notes as an aid memoire. This is the second time I have seen them present in the last year, so some of the slides were familiar. Steve Stamp (CFO) gave the presentation (unfortunately there were no slide handouts so I cannot vouch for accuracy of numbers in my notes). Summary details: * Market Cap circa £50M, Revenue around £30M, EBITDA positive * 100+ clients, 300 clinical studies, 50K patients, 350 employees. * Ergomed has an unusual and diversified business model which consists of four main activities (CRO activities, Pharmacovigilance, co-development portfolio and Ergomed development portfolio). CRO activities: This specialises in a small number of areas (oncology, neurology, immunology and rare diseases, they won’t take on programs which require large studies like diabetes or asthma). This is a profitable part of the business but profits recycled to build co-development portfolio of drugs where Ergomed have a shared interest (5-15%) with the trial sponsor. Ergomed are continuing to buy and build the CRO business as small CRO companies can currently be acquired for 8X EBITDA. Pharmacovigilance: This is profitable with a 30-40% gross margin and demand for services is growing with large pharma outsourcing. Once signed up clients are sticky. Ergomed would like to acquire more businesses like this but they are hard to find. Co development portfolio: This currently consists of 5 products, which cost them the equivalent to £3M last year (not sure about previous years), they were acquired through discounting the CRO fee (discount 30 – 50%) with client companies who are using Ergomed as CRO for clinical studies on the 5 compounds (note there used to be 6 compounds one failed). Ergomed receives a fixed percentage of future royalties and milestone payments which are between 5 and 15% (of the partners income from the compound, not from gross sales should the partner outlicence to a large pharma). In some cases the client has negotiated a cap on the total fees/income receivable by Ergomed. Ergomed 100% owned development portfolio: This consists of two products (Haemostatix) to reduce/eliminate bleeding during surgery which sounded quite low tech, basically a biocompatible occlusive liquid and a biocompatible gel which have convenience advantages over existing products. When asked about the relative value assigned by the brokers to the different parts of the business we were told it was £53m for the combined CRO and pharmacovigilance divisions, £15m for the co-development portfolio, £20m for their own Haemostatix development portfolio and £12m cash. The market cap is currently around £50m (share price circa 120p) and the last placing at 140p per share to fund the latest acquisitions was two months ago (May 2016). What I like about the company is the potential royalty stream from the shared interest portfolio and the existing cash generating CRO and Pharmacovigilance service activities. What I don’t particularly like is that they are also diversified into developing their own products (Haemostatix) and I am always suspicious of continuous buy and build strategies, which is what they are doing for the CRO and pharmacovigilance services and it is how they acquired the Haemostatix develop portfolio. These will stay on my watch list for now, I would be more interested if they sold off Haemostatix and concentrated on organic growth rather than buy and build on the services whilst simultaneously growing the value of the co-development portfolio.
04/5/2016
13:45
rivaldo: Not a holder here, but been watching for a long time puzzled by the share price fall, and now I know the reason. The placing at 140p is fair enough, but imo the entire attraction of this company has been destroyed by today's transaction. I liked the combination of a reasonably low P/E combined with little downside and large upside from the investments in higher-risk drugs via the investment of costs. Today's acquisition commits ERGO to long-term development with no commercialisation until 2020 at the earliest. The "intention for Ergomed to remain profitable at the EBITDA level" is just a sop. The entire rationale for investing has been completely changed. Why couldn't they just continue to do what they were doing? ERGO is uninvestable for me now. It will likely come off my watchlist unless someone/something changes my mind.
23/7/2015
15:40
buffetteer: Minx 2 sides of the business -one doing clinical trials and pharma records for pharma companies .both growing very well - 15& 30% respectively .This market for out-sourced services is growing . The other part is the co-development of 5 drugs that Ergo have given clinical trial discounts to in order to share in the upside .Arguably there is no value in the share price of these phase 2 & 3 trials .This has cost the company over £2m in reduced profitability but the opportunity is tens of millions .The first is due end of year I think . Personally if were you I would read the strategy note in the annual accounts which gives a lot of detail in what this exciting company is doing .It is backed up by a first class non -exec Chairman and 2 other non-execs -all of whom are very highly rated and experienced operators who would not have joined this small company for the fun of it .
14/5/2015
14:56
proactivest: Video interview with CEO Reljanovic http://tinyurl.com/k56vs2z Dr Miroslav Reljanovic, chief executive of Ergomed (LON:ERGO), says the company believes it can increase its share price further, which he claims is still undervalued even after a 20% rise over the last six months. Reljanovic believes the acquisition strategy, coupled with newsflow over the coming months, should help the stock to continue its journey north. Ergomed’s CEO says it’s hard to pin down the exact size of the potential market but says the market for oncology treatments in general is very large. The company floated on AIM in July last year, raising £11mln to fund its ambitious growth plans.
Ergomed share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20170729 11:57:21